You are here

SARC002

Completed
Phase 3 randomized trial of 120-minute infusion gemcitabine v. 90-minute infusion gemcitabine plus docetazel in unresectable soft tissue sarcoma: A multi-disciplinary trial of the North American sarcoma study group of the Connective Tissue Oncology Societ
Type of Sarcoma: 
Unresectable soft tissue sarcoma
Drug: 
Gemcitabine and Docetaxel
Accrual Status: 
Closed
Overall Study Principal Investigator: 

Robert Maki, MD, PhD
Professor Pediatrics, Hematology & Oncology
Hofstra-Northwell School of Medicine

For more information about this trial and open sites: